What should the nurse monitor for in patients taking liraglutide?

Monitoring for signs of thyroid dysfunction in patients taking liraglutide is essential due to the drug's association with thyroid C-cell tumors in animal studies, which raises concerns about its potential effects in humans. While definitive evidence of such tumors in humans has not been established, the possibility warrants vigilance for symptoms such as a lump or mass in the neck, altered voice, or difficulty swallowing, which could indicate thyroid issues.

The other options, while important in general patient care, are not specifically linked to liraglutide therapy. For instance, dehydration could be a consideration in cases of gastrointestinal side effects such as nausea and vomiting, but it is not a primary monitoring focus. Fluid overload may occur in individuals with certain co-morbidities, but it is not a direct concern associated with liraglutide. Issues related to liver dysfunction are also relevant in broader patient management contexts but are not specifically highlighted due to liraglutide's profile. Consequently, monitoring for thyroid dysfunction stands out as a significant point of focus for patients on this medication.